Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of intravenous efgartigimod in adult primary immune thrombocytopenia
2019-002100-41Phase 3Completed
- Sponsor
- argenx
- Start
- Aug 2019
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in immune thrombocytopenia (ITP) comparing Efgartigimod alfa intravenous with Placebo intravenous (2 arms). Primary endpoint: Sustained platelet count response. Started Aug 2019; status: completed.
02
Drugs
efgartigimod alfa
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on 2019-002100-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002100-41.